PMID- 36854513
OWN - NLM
STAT- MEDLINE
DCOM- 20230302
LR  - 20230302
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 43
IP  - 3
DP  - 2023 Mar
TI  - Efficacy and Safety of Lenvatinib After Progression on First-line Atezolizumab 
      Plus Bevacizumab Treatment in Advanced Hepatocellular Carcinoma Patients.
PG  - 1377-1384
LID - 10.21873/anticanres.16286 [doi]
AB  - BACKGROUND/AIM: This study aimed to assess the clinical impact of lenvatinib 
      after disease progression on atezolizumab plus bevacizumab in patients with 
      advanced hepatocellular carcinoma (HCC). PATIENTS AND METHODS: A total of 14 
      patients who received lenvatinib after failure of atezolizumab plus bevacizumab 
      and all patients were classified as having a Barcelona Clinic Liver Cancer stage 
      C. Six patients had macrovascular invasion, and a liver occupation rate of >50% 
      was reported in seven patients. The Kaplan-Meier method was performed to analyze 
      the cumulative survival, while log-rank test was used to detect the differences. 
      The dose of lenvatinib was determined based on body weight. RESULTS: The 
      participants' responses to lenvatinib treatment were as follows: 21.4% achieved 
      partial response (PR), while 35.7% had a stable disease, with a disease control 
      rate of 57.1%. The median progression-free survival (PFS) and overall survival 
      (OS) were 4.2 months and 8.3 months, respectively; the median PFS and OS were 6.7 
      months and 10.5 months in the PR group. No significant difference was observed in 
      the median PFS and OS between patients with and without macrovascular invasion or 
      liver occupation rate of >50%. Most of the adverse events (AEs) were categorized 
      as grade 1-2; all patients tolerated the AEs, and no drug-related mortality was 
      reported. Additionally, half of the population underwent subsequent therapy after 
      progression on lenvatinib treatment. CONCLUSION: Lenvatinib is effective and can 
      be safely used as second-line systemic therapy after progression on atezolizumab 
      plus bevacizumab in patients with advanced HCC in real-world clinical practice.
CI  - Copyright (c) 2023 International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chen, Yen-Hao
AU  - Chen YH
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 
      Taiwan, R.O.C.; alex8701125@gmail.com.
AD  - School of Medicine, College of Medicine, Chang Gung University, Taoyuan, Taiwan, 
      R.O.C.
AD  - School of Medicine, Chung Shan Medical University, Taichung, Taiwan, R.O.C.
AD  - Department of Nursing, School of Nursing, Fooyin University, Kaohsiung, Taiwan, 
      R.O.C.
FAU - Chen, Yen-Yang
AU  - Chen YY
AD  - Division of Hematology-Oncology, Department of Internal Medicine, Kaohsiung Chang 
      Gung Memorial Hospital and Chang Gung University College of Medicine, Kaohsiung, 
      Taiwan, R.O.C.
FAU - Wang, Jing-Houng
AU  - Wang JH
AD  - Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 
      Kaohsiung, Taiwan, R.O.C.
FAU - Hung, Chao-Hung
AU  - Hung CH
AD  - Division of Hepatogastroenterology, Department of Internal Medicine, Kaohsiung 
      Chang Gung Memorial Hospital and Chang Gung University College of Medicine, 
      Kaohsiung, Taiwan, R.O.C.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 52CMI0WC3Y (atezolizumab)
RN  - EE083865G2 (lenvatinib)
RN  - 2S9ZZM9Q9V (Bevacizumab)
SB  - IM
MH  - Humans
MH  - *Carcinoma, Hepatocellular/drug therapy
MH  - Bevacizumab/adverse effects
MH  - *Liver Neoplasms/drug therapy
OTO - NOTNLM
OT  - Atezolizumab
OT  - bevacizumab
OT  - hepatocellular carcinoma
OT  - lenvatinib
EDAT- 2023/03/01 06:00
MHDA- 2023/03/03 06:00
CRDT- 2023/02/28 20:44
PHST- 2022/12/14 00:00 [received]
PHST- 2022/12/22 00:00 [revised]
PHST- 2022/12/23 00:00 [accepted]
PHST- 2023/02/28 20:44 [entrez]
PHST- 2023/03/01 06:00 [pubmed]
PHST- 2023/03/03 06:00 [medline]
AID - 43/3/1377 [pii]
AID - 10.21873/anticanres.16286 [doi]
PST - ppublish
SO  - Anticancer Res. 2023 Mar;43(3):1377-1384. doi: 10.21873/anticanres.16286.